Cubosomes in cancer drug delivery: A review

Ryan Varghese; Sahil Salvi; Purab Sood; Bhargavi Kulkarni; Dileep Kumar

doi:10.1016/j.colcom.2021.100561

Cubosomes in cancer drug delivery: A review

Ryan Varghese
, Sahil Salvi
, Purab Sood
, Bhargavi Kulkarni
, Dileep Kumar^*

^*Corresponding author for this work

Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal

Research output: Contribution to journal › Review article › peer-review

81 Citations (Scopus)

Abstract

The lyotropic nonlamellar liquid crystalline nanoparticles (LCNs), especially cubosomes are gaining utility and acceptance as a drug delivery system, in diseases like cancer. These cubosomes are highly versatile carriers with promising theranostic efficiency and can be administered via oral, topical, or intravenous modalities. Over the recent years, significant research has facilitated the improvement in the efficacy, preparation, characterization, target selectivity, and controlling drug release profiles of the loaded anticancer bioactive. Nonetheless, its clinical translation has been slow and additionally requires concrete evidence. This review underscores the recent advances and impediments in the development and application of cubosomes against various cancers and discussing the hurdles faced in segueing it into a potential nanotechnological intervention.

Original language	English
Article number	100561
Journal	Colloids and Interface Science Communications
Volume	46
DOIs	https://doi.org/10.1016/j.colcom.2021.100561
Publication status	Published - 01-2022

All Science Journal Classification (ASJC) codes

Biotechnology
Physical and Theoretical Chemistry
Surfaces, Coatings and Films
Colloid and Surface Chemistry
Materials Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.colcom.2021.100561

Cite this

@article{a1517a7442e048fa94ba3b73788282e1,

title = "Cubosomes in cancer drug delivery: A review",

abstract = "The lyotropic nonlamellar liquid crystalline nanoparticles (LCNs), especially cubosomes are gaining utility and acceptance as a drug delivery system, in diseases like cancer. These cubosomes are highly versatile carriers with promising theranostic efficiency and can be administered via oral, topical, or intravenous modalities. Over the recent years, significant research has facilitated the improvement in the efficacy, preparation, characterization, target selectivity, and controlling drug release profiles of the loaded anticancer bioactive. Nonetheless, its clinical translation has been slow and additionally requires concrete evidence. This review underscores the recent advances and impediments in the development and application of cubosomes against various cancers and discussing the hurdles faced in segueing it into a potential nanotechnological intervention.",

author = "Ryan Varghese and Sahil Salvi and Purab Sood and Bhargavi Kulkarni and Dileep Kumar",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = jan,

doi = "10.1016/j.colcom.2021.100561",

language = "English",

volume = "46",

journal = "Colloids and Interface Science Communications",

issn = "2215-0382",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Cubosomes in cancer drug delivery

T2 - A review

AU - Varghese, Ryan

AU - Salvi, Sahil

AU - Sood, Purab

AU - Kulkarni, Bhargavi

AU - Kumar, Dileep

PY - 2022/1

Y1 - 2022/1

N2 - The lyotropic nonlamellar liquid crystalline nanoparticles (LCNs), especially cubosomes are gaining utility and acceptance as a drug delivery system, in diseases like cancer. These cubosomes are highly versatile carriers with promising theranostic efficiency and can be administered via oral, topical, or intravenous modalities. Over the recent years, significant research has facilitated the improvement in the efficacy, preparation, characterization, target selectivity, and controlling drug release profiles of the loaded anticancer bioactive. Nonetheless, its clinical translation has been slow and additionally requires concrete evidence. This review underscores the recent advances and impediments in the development and application of cubosomes against various cancers and discussing the hurdles faced in segueing it into a potential nanotechnological intervention.

AB - The lyotropic nonlamellar liquid crystalline nanoparticles (LCNs), especially cubosomes are gaining utility and acceptance as a drug delivery system, in diseases like cancer. These cubosomes are highly versatile carriers with promising theranostic efficiency and can be administered via oral, topical, or intravenous modalities. Over the recent years, significant research has facilitated the improvement in the efficacy, preparation, characterization, target selectivity, and controlling drug release profiles of the loaded anticancer bioactive. Nonetheless, its clinical translation has been slow and additionally requires concrete evidence. This review underscores the recent advances and impediments in the development and application of cubosomes against various cancers and discussing the hurdles faced in segueing it into a potential nanotechnological intervention.

UR - https://www.scopus.com/pages/publications/85120619273

UR - https://www.scopus.com/pages/publications/85120619273#tab=citedBy

U2 - 10.1016/j.colcom.2021.100561

DO - 10.1016/j.colcom.2021.100561

M3 - Review article

AN - SCOPUS:85120619273

SN - 2215-0382

VL - 46

JO - Colloids and Interface Science Communications

JF - Colloids and Interface Science Communications

M1 - 100561

ER -

Cubosomes in cancer drug delivery: A review

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this